Compare Stocks: CALC, AGFY, SCYX, and GRCE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGFY Agrify	$23.01 -2.0%	$22.04	$13.22 ▼ $48.84	$46.09M	9.96	31,892 shs	4,988 shs
CALC CalciMedica	$1.72 -1.4%	$2.87	$1.62 ▼ $36.00	$11.71M	0.83	193,016 shs	21,566 shs
GRCE Grace Therapeutics	$2.11 -2.5%	$2.18	$1.79 ▼ $5.18	$44.29M	0.44	389,030 shs	51,363 shs
SCYX SCYNEXIS	$4.43 -0.4%	$4.78	$3.53 ▼ $9.12	$44.20M	1.11	89,764 shs	22,072 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGFY Agrify	-1.96%	+10.23%	+0.22%	-15.99%	-39.19%
CALC CalciMedica	-2.79%	-11.68%	-40.82%	-57.35%	-88.88%
GRCE Grace Therapeutics	+1.89%	+1.41%	-1.82%	-9.05%	-30.32%
SCYX SCYNEXIS	-4.09%	0.00%	-14.26%	+15.58%	-48.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGFY Agrify	$23.01 -2.0%	$22.04	$13.22 ▼ $48.84	$46.09M	9.96	31,892 shs	4,988 shs
CALC CalciMedica	$1.72 -1.4%	$2.87	$1.62 ▼ $36.00	$11.71M	0.83	193,016 shs	21,566 shs
GRCE Grace Therapeutics	$2.11 -2.5%	$2.18	$1.79 ▼ $5.18	$44.29M	0.44	389,030 shs	51,363 shs
SCYX SCYNEXIS	$4.43 -0.4%	$4.78	$3.53 ▼ $9.12	$44.20M	1.11	89,764 shs	22,072 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGFY Agrify	-1.96%	+10.23%	+0.22%	-15.99%	-39.19%
CALC CalciMedica	-2.79%	-11.68%	-40.82%	-57.35%	-88.88%
GRCE Grace Therapeutics	+1.89%	+1.41%	-1.82%	-9.05%	-30.32%
SCYX SCYNEXIS	-4.09%	0.00%	-14.26%	+15.58%	-48.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGFY Agrify	0.00	N/A	N/A	N/A
CALC CalciMedica	2.20	Hold	$50.00	2,815.45% Upside
GRCE Grace Therapeutics	2.00	Hold	$6.00	185.04% Upside
SCYX SCYNEXIS	2.33	Hold	$33.00	644.75% Upside

Current Analyst Ratings Breakdown

Latest CALC, AGFY, SCYX, and GRCE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	CALC CalciMedica	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/13/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	CALC CalciMedica	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/13/2026	SCYX SCYNEXIS	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$24.00 ➝ $33.00
8/3/2026	GRCE Grace Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/31/2026	SCYX SCYNEXIS	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/29/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/24/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	GRCE Grace Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGFY Agrify	$12.26M	3.76	N/A	N/A	$10.47 per share	2.20
CALC CalciMedica	N/A	N/A	N/A	N/A	($2.30) per share	N/A
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	$3.99 per share	N/A
SCYX SCYNEXIS	$19.22M	2.29	N/A	N/A	$9.07 per share	0.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGFY Agrify	-$41.75M	-$22.65	N/A	N/A	N/A	-424.11%	-185.90%	-72.67%	N/A
CALC CalciMedica	-$29.56M	-$6.80	N/A	N/A	N/A	N/A	-863.40%	-155.24%	11/11/2026 (Estimated)
GRCE Grace Therapeutics	-$7.79M	-$1.18	N/A	N/A	N/A	N/A	-36.11%	-34.39%	11/12/2026 (Estimated)
SCYX SCYNEXIS	-$8.61M	-$2.09	N/A	N/A	N/A	-41.79%	-44.15%	-32.61%	11/4/2026 (Estimated)

Latest CALC, AGFY, SCYX, and GRCE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	GRCE Grace Therapeutics	-$0.1293	-$0.91	-$0.7807	-$0.91	$0.40 million	N/A
8/11/2026	Q2 2026	CALC CalciMedica	-$1.4250	-$0.45	+$0.9750	-$2.25	N/A	N/A
8/10/2026	Q2 2026	SCYX SCYNEXIS	-$0.5067	$0.63	+$1.1367	$0.63	$0.08 million	$0.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGFY Agrify	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGFY Agrify	1.43	2.64	2.52
CALC CalciMedica	1.67	5.58	5.58
GRCE Grace Therapeutics	N/A	11.47	11.47
SCYX SCYNEXIS	N/A	9.65	9.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGFY Agrify	5.98%
CALC CalciMedica	N/A
GRCE Grace Therapeutics	6.08%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
AGFY Agrify	2.16%
CALC CalciMedica	28.25%
GRCE Grace Therapeutics	10.84%
SCYX SCYNEXIS	4.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGFY Agrify	140	2.00 million	1.96 million	Not Optionable
CALC CalciMedica	15	6.83 million	4.90 million	No Data
GRCE Grace Therapeutics	5	21.04 million	18.76 million	N/A
SCYX SCYNEXIS	29	9.95 million	9.54 million	Optionable

CALC, AGFY, SCYX, and GRCE Headlines

Recent News About These Companies

SCYNEXIS (NASDAQ:SCYX) Shares Pass Above 50-Day Moving Average - Time to Sell?

September 23 at 4:01 AM | americanbankingnews.com

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

September 22 at 11:14 PM | markets.businessinsider.com

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.

September 22 at 8:00 AM | globenewswire.com

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

September 15, 2026 | globenewswire.com

SCYNEXIS Names Sanjay Subramanian as CFO

September 10, 2026 | finance.yahoo.com

Scynexis Names Sanjay Subramanian CFO

September 10, 2026 | rttnews.com

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

September 10, 2026 | globenewswire.com

SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above Fifty Day Moving Average - Here's What Happened

September 9, 2026 | marketbeat.com

SCYNEXIS to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

SCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average - Should You Sell?

September 1, 2026 | marketbeat.com

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

August 25, 2026 | globenewswire.com

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026 | tmcnet.com

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

June 30, 2026 | globenewswire.com

SCYNEXIS Shareholders Approve Governance and Equity Plan Changes

June 26, 2026 | tipranks.com

SCYNEXIS Inc.

June 24, 2026 | marketwatch.com

SCYNEXIS Announces One-for-Eight Reverse Stock Split

May 22, 2026 | globenewswire.com

SCYNEXIS (SCYX) price target increased by 20.73% to 4.28

May 14, 2026 | msn.com

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 11, 2026 | globenewswire.com

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2026 | globenewswire.com

SCYNEXIS Raises $40 Million in Strategic Private Placement

April 19, 2026 | theglobeandmail.com

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

March 31, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC, AGFY, SCYX, and GRCE Company Descriptions

Agrify NASDAQ:AGFY

$23.01 -0.46 (-1.96%)

As of 09/23/2026

Agrify Corporation offers hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. It offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. The company also provides associated services comprising consulting, engineering, and construction. In addition, the company offers hydrocarbon, alcohol, solventless, post-processing, and lab equipment, as well as provides indoor farming solutions. In addition, it offers equipment and services in a contract and purchase order. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Troy, Michigan.

CalciMedica NASDAQ:CALC

$1.72 -0.03 (-1.44%)

As of 01:37 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Grace Therapeutics NASDAQ:GRCE

$2.10 -0.06 (-2.55%)

As of 01:37 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

SCYNEXIS NASDAQ:SCYX

$4.43 -0.02 (-0.43%)

As of 01:37 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CALC, AGFY, SCYX, and GRCE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CALC, AGFY, SCYX, and GRCE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CALC, AGFY, SCYX, and GRCE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC, AGFY, SCYX, and GRCE Company Descriptions

Agrify NASDAQ:AGFY

CalciMedica NASDAQ:CALC

Grace Therapeutics NASDAQ:GRCE

SCYNEXIS NASDAQ:SCYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CALC, AGFY, SCYX, and GRCE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CALC, AGFY, SCYX, and GRCE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CALC, AGFY, SCYX, and GRCE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC, AGFY, SCYX, and GRCE Company Descriptions

Agrify NASDAQ:AGFY

CalciMedica NASDAQ:CALC

Grace Therapeutics NASDAQ:GRCE

SCYNEXIS NASDAQ:SCYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools